Physician profile
John E Port
NPI 1912936154
$11,802.37
in general payments reported to CMS, 2019-2025
65 companies · $542 in 2025
The $542 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,518 · 2020: $1,266 · 2021: $3,179 · 2022: $2,461 · 2023: $2,187 · 2024: $649 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,364 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,363.99 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,221.61 | 2021 | |
| Abbvie INC. | $915.70 | 2019-2023 | |
| Amgen INC. | $845.79 | 2019-2024 | Repatha, Otezla, Prolia |
| Novo Nordisk INC | $786.15 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $675.85 | 2019-2025 | Emgality, Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals Lp | $615.97 | 2019-2025 | Breztri, Wainua, Bevespi Aerosphere |
| Boehringer Ingelheim Pharmaceuticals, INC. | $546.29 | 2019-2023 | Jardiance |
| Pfizer INC. | $382.62 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $331.73 | 2019-2023 | Belsomra, Steglatro, Vaxneuvance |
| Abbott Laboratories | $321.12 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $317.20 | 2019-2023 | Trelegy Ellipta |
| Allergan, INC. | $240.09 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $234.65 | 2020-2023 | Trintellix |
| Insightec,INC | $231.65 | 2022-2024 | Exablate |
| Dexcom, INC. | $231.49 | 2021-2025 | Dexcom G6 Transmitter |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Port listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.